Over five million people around the world suffer from Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis (UC) and Crohn’s Disease (CD) and the incidence has been steadily rising.
The area is one of the most active in biopharmaceutical development, with hundreds of trials in progress, many with the potential to deliver breakthrough therapies. Trial participants typically are suffering from active flare-ups, and competition for highly specialized investigators and interested patients is intense.
At ICON, we’re able to surmount the challenges you face in IBD development by bringing deep therapeutic expertise, process and technology innovation, and an integrated approach to the full course of compound development. In the past seven years, we’ve conducted: